Insmed Reports Resignation of Chief Commercial Officer J. Drayton Wise


Insmed Incorporated (Nasdaq: INSM) announced that J. Drayton Wise has resigned from his position as Chief Commercial Officer, effective immediately. His departure was attributed to personal and medical reasons and was not connected to the company’s financial condition, operations, or any internal disagreements.

Following his resignation, Mr. Wise has entered into a consulting agreement with Insmed. Under the terms of this agreement, he will remain available to the company through the end of the year, with automatic three-month extensions possible unless terminated by mutual agreement. He will receive a consulting fee of $30,000 per month during the initial consulting period and $20,000 per month during any extensions.

Additionally, Mr. Wise’s outstanding equity awards will continue to vest while the consulting relationship is active. Vested stock options will remain exercisable until three months after the end of his service or until their original expiration date, whichever comes first.

No successor to the Chief Commercial Officer role has been named.

Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) does not currently plan to hold an advisory committee meeting to discuss the company’s New Drug Application (NDA) for brensocatib, a treatment for patients with non-cystic fibrosis bronchiectasis. The FDA had previously granted priority review to the NDA and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act.

source: Insmed Incorporated, form 8-K filing, February 24, 2025.

Insmed reported strong financial results for the fourth quarter and full-year 2024, highlighted by a 19% increase in total revenue for ARIKAYCE, which reached $363.7 million, exceeding the upper end of guidance. The company reiterated its 2025 global revenue outlook for ARIKAYCE at $405 million to $425 million, reflecting continued double-digit growth.

A major milestone was the FDA’s acceptance of Insmed’s New Drug Application (NDA) for brensocatib for bronchiectasis, granting Priority Review with a target action date of August 12, 2025. If approved, a U.S. launch is expected in the third quarter of 2025, with regulatory submissions in the EU, UK, and Japan planned for later in the year.

The company also made progress across its pipeline, completing enrollment for the Phase 3 ENCORE study of ARIKAYCE for Mycobacterium avium complex (MAC) lung disease, with topline data expected in Q1 2026. Meanwhile, the Phase 2b study of TPIP for pulmonary arterial hypertension (PAH) is set to report topline results in mid-2025, and a Phase 3 study for TPIP in pulmonary hypertension associated with interstitial lung disease (PH-ILD) is planned for the second half of the year.

Insmed ended 2024 with a strong cash position of approximately $1.4 billion, supporting its continued investment in growth. CEO Will Lewis emphasized that the company is well-positioned for a transformative 2025, balancing commercial execution with pipeline expansion, including new gene therapy programs for Duchenne muscular dystrophy (DMD), ALS, and Stargardt disease.

Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for brensocatib, intended for patients with non-cystic fibrosis bronchiectasis. The FDA has granted priority review for the application and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act.